跳至主要内容
临床试验/DRKS00034348
DRKS00034348招募中3 期

Randomised, controlled trial to evaluate the effectiveness of Oviva Direkt in reducing blood pressure in patients with hypertension - HYPE

Oviva AG0 个研究点目标入组 134 人开始时间: 2024年6月10日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
134

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • ? Fulfilling the criteria for essential hypertension, which is an average systolic blood pressure > 135 mmHg measured at rest with validated devices and according to the 2023 ESH Guidelines for the management of arterial hypertension for home-blood pressure monitoring
  • ? Stable antihypertensive treatment for at least three months
  • ? Concurrent use of fewer than 4 antihypertensive drugs
  • ? Treatment goal to reduce systolic blood pressure using a lifestyle intervention
  • ? Valid and working email address, telephone number, and internet access
  • ? Sufficient skill in the German language for participation
  • ? Signed informed consent
  • ? Smartphone available and compatible with the Oviva Direkt app
  • ? Possession of a validated blood pressure monitor
  • ? Motivation and ability to make lifestyle changes

排除标准

  • ? Average systolic blood pressure at rest = 180 mmHg
  • ? Patient safety reasons (e.g., breastfeeding, pregnancy, concurrent insulin treatment)
  • ? Cardiovascular event in the last 6 months (e.g., stroke, heart attack, cerebral haemorrhage)
  • ? Severe cognitive and intellectual impairment
  • ? Current or recent participation (within the past 12 months) in a digital lifestyle intervention or clinical investigation targeting blood pressure and/or body weight reduction
  • ? Weight loss >5% in the past 6 months (intentional or unintentional)
  • ? Living in a household with another study participant for a digital lifestyle intervention
  • ? Terminal diagnosis with a life expectancy of less than 24 months
  • ? Planned long-term absence > 3 weeks

研究者

发起方
Oviva AG

相似试验